The focus of my research group is to understand the immune mechanisms involved in chronic inflammatory eye diseases, in order to improve therapeutic strategies. Currently steroids and cyclosporin are the mainstay immunosuppressives for treating the chronic inflammatory diseases of the retina (uveitis) and ocular surface (chronic allergic eye disease, ketaroconjunctivitis sicca). Although they can be effective in dampening the inflammation, not all patients respond and  these drugs can have serious side-effects in the eye including cataract formation and glaucoma. There is therefore a need for more specific treatments to intervene on the specific immune pathways involved in this diverse range of clinical situations.
The role of effector CD4+T cell subsets and their cytokines has been investigated in experimental models and in human tissues, fluids and tissue-derived cell populations. The different proportions of TH1, TH2, Treg and TH17 subsets, and their cytokine profiles, is a likely explanation for the varied responses of individuals to therapies, and the range of clinical severities in each subtype of disease.
We are now focussing on applying novel anti-inflammatory agents to various experimental models of uveitis and allergic eye disease, to further unravel the molecular mechanisms involved in each subtype of ocular disease.